司帕沙星衍生物(YH37)体外抗微生物活性研究

摘要

The susceptibilities of mycoplasma and bacteria to the derivative(YH37)of sparfloxacin was determined by microdilution method in vitro.Results showed that the minimum inhibition concentration(MICgo)of YH37 against Mycoplasma hominis(Mh)(0.25mg/L),and Ureaplasma urealyticum(Uu)(1.0rag/L),were 1/8 those of sparfloxacin against Mh,and 1/4 those of sparfloxacin against Uu.YH37 was still highly susceptibility to quinolone-resistant strains of Mh and Uu.Its MICs were 1/4～1/16 of that of ciprofloxacin,respectively.MICs of YH37 for bacteria were 1/8～1/16 of that of levofloxacin and 1/2 of that of sparfloxacin.%采用微量稀释法测定了5-氨基-1-环丙基-6,8-二氟-1,4-二氢-7-(3-甲基-1-哌嗪基)-4-氧代喹啉-6-羧酸(YH37)对临床分离的人型支原体(Mh)、解脲脲原体(Uu)以及细菌标准菌株的体外敏感性.结果显示,YH37对Mh的抑制活性较强,MIC90为0.25mg/L,是司帕沙星的1/8;对Uu的MIC90为1mg/L,是司帕沙星的1/4.YH37对Mh、Uu的喹诺酮耐药株有一定的抑制活性,其MIC分别为CPLX的1/4～1/16.YH37对被测细菌的抑制活性是左氧氟沙星的1/8～1/16,是司帕沙星的1/2.